Minervini SEPA — 8 Parameter Audit
| Parameter | Result | Data |
|---|---|---|
|
Price above 150 & 200 DMA
Minervini SEPA · Criterion 1
|
FAIL | Price ₹172 · 150 DMA ₹192 · 200 DMA ₹177 |
|
150 DMA above 200 DMA
Minervini SEPA · Criterion 2
|
PASS | 150 DMA ₹192 vs 200 DMA ₹177 (+8.6%) |
|
200 DMA trending up ≥ 1 month
Minervini SEPA · Criterion 3
|
PASS | 200 DMA slope: +2.75% over 4 weeks |
|
50 DMA above 150 & 200 DMA
Minervini SEPA · Criterion 4
|
PASS | 50 DMA ₹195 · 150 DMA ₹192 · 200 DMA ₹177 |
|
Price above 50 DMA
Minervini SEPA · Criterion 5
|
FAIL | Price ₹172 · 50 DMA ₹195 (-12.0%) |
|
Price within 25% of 52-week high
Minervini SEPA · Criterion 6
|
FAIL | ₹172 vs 52W high ₹289 (-40.6%) |
|
Price ≥ 30% above 52-week low
Minervini SEPA · Criterion 7
|
PASS | ₹172 vs 52W low ₹108 (+59.0%) |
|
RS Rating ≥ 70
Minervini SEPA · Criterion 8
|
PASS | RS Rating: 78 (threshold: ≥70) |
Weinstein Stage Analysis
Base Stage 2
Advance Stage 3
Top Stage 4
Decline
SPARC.NS is in Weinstein Stage 1 — the basing phase. The stock is consolidating after a prior decline, trading sideways around or below its 200-day moving average. Position traders applying strict methodology do not participate during Stage 1.
Relative Strength Rating
Structural Analysis
Sun Pharma Advanced Research Company Limited is currently trading 12.0% below its 50-day moving average, with Weinstein Stage 1 confirmed by the moving average hierarchy.
The Minervini SEPA audit finds 5 of 8 parameters confirmed. The parameter(s) not confirmed: Price above 150 & 200 DMA, Price above 50 DMA, Within 25% of 52W high.
Sanjaya's Reading
Mitra, main dekh raha hoon Sun Pharma Advanced Research Company Limited ko — 5 criteria poore hain aath mein se.
Weinstein Stage 1 mein hai yeh instrument. अभी नहीं मित्र.
This is a static snapshot
This audit was generated from NSE closing data on 23 October 2026. Run a live audit with real-time data, animated criteria reveals, and Sanjaya's full narration.
Run a Live Audit — Free →Free tier includes Nifty 50 stocks · Pro unlocks full NSE universe
Frequently Asked Questions
SPARC (Sun Pharma Advanced Research Company Limited) currently meets 5 of 8 Minervini SEPA parameters. SPARC currently meets 5 of 8 Minervini SEPA parameters. The parameter(s) not confirmed: Price above 150 & 200 DMA, Price above 50 DMA, Within 25% of 52W high.
SPARC is currently in Weinstein Stage 1. SPARC.NS is in Weinstein Stage 1 — the basing phase. The stock is consolidating after a prior decline, trading sideways around or below its 200-day moving average. Position traders applying strict methodology do not participate during Stage 1.
The Kasauti verdict for SPARC is अभी नहीं मित्र (Does Not Pass Yet). The Kasauti verdict for SPARC.NS is अभी नहीं मित्र — Does Not Pass Yet. With 5 of 8 criteria met, the primary area to monitor is: Price above 150 & 200 DMA, Price above 50 DMA, Within 25% of 52W high. This is a structural methodology assessment only — not a recommendation to deploy or exit capital. This is a structural methodology assessment only — not a recommendation to deploy or exit capital.